Literature DB >> 14723256

Rhinocerebral mucormycosis in Taiwan.

Boon-Siang Khor1, Ming-Hsun Lee, Hsieh-Shong Leu, Jien-Wei Liu.   

Abstract

To understand the demographic as well as clinical characteristics, and outcomes of patients with rhinocerebral mucormycosis in Taiwan, we retrospectively analyzed patients with this disease admitted to Chang Gung Memorial Hospital-Kaohsiung from 1988 through 2000. The 21 patients included 8 men (28%) and 13 women (62%). The median age was 60 years (range, 34-82 years). Twenty patients (95%) had underlying diabetes mellitus. The most common clinical feature at admission was ocular lesions, followed by headache, nostril lesions, and consciousness disturbance. Fifteen (94%) of 16 patients who received combined surgical debridement and therapy with amphotericin B survived, while only 1 (20%) of the 5 patients who received amphotericin B alone survived (p=0.004). The diagnosis of rhinocerebral mucormycosis was delayed in 4 patients (19%). Of the 16 patients who survived, 1 (6%) had delayed diagnosis, while of the 5 patients who died, 3 (60%) had delayed diagnoses (p=0.028). This series disclosed a higher proportion of patients with rhinocerebral mucormycosis in Taiwan had underlying diabetes mellitus, and ocular lesions were more frequent than nostril lesions at the time of admission. These results highlight the importance of the timely initiation of a combination of aggressive surgical debridement and treatment with amphotericin B in patients with rhinocerebral mucormycosis. Considering the high rate of delayed diagnosis, improved clinician's awareness of mucormycosis is extremely important and is in urgent need in Taiwan.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14723256

Source DB:  PubMed          Journal:  J Microbiol Immunol Infect        ISSN: 1684-1182            Impact factor:   4.399


  13 in total

1.  Gastrointestinal mucormycosis: an evolving disease.

Authors:  Brad Spellberg
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-02

2.  Acute invasive fungal rhinosinusitis: our experience with 18 cases.

Authors:  Mehdi Bakhshaee; Amin Bojdi; Abolghasem Allahyari; Mohammad Reza Majidi; Sherwin Tavakol; Mohammad Javad Najafzadeh; Masoud Asghari
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-06-07       Impact factor: 2.503

Review 3.  Novel perspectives on mucormycosis: pathophysiology, presentation, and management.

Authors:  Brad Spellberg; John Edwards; Ashraf Ibrahim
Journal:  Clin Microbiol Rev       Date:  2005-07       Impact factor: 26.132

4.  Mucormycosis in immunochallenged patients.

Authors:  Jane Pak; Veronica T Tucci; Albert L Vincent; Ramon L Sandin; John N Greene
Journal:  J Emerg Trauma Shock       Date:  2008-07

5.  Recent advances in the treatment of mucormycosis.

Authors:  Brad Spellberg; Ashraf S Ibrahim
Journal:  Curr Infect Dis Rep       Date:  2010-11       Impact factor: 3.725

Review 6.  Recent advances in the management of mucormycosis: from bench to bedside.

Authors:  Brad Spellberg; Thomas J Walsh; Dimitrios P Kontoyiannis; John Edwards; Ashraf S Ibrahim
Journal:  Clin Infect Dis       Date:  2009-06-15       Impact factor: 9.079

7.  Rhinocerebral Mucormycosis Among Diabetic Patients: An Emerging Trend.

Authors:  Sujatha S Reddy; N Rakesh; Pallavi Chauhan; Shivani Sharma
Journal:  Mycopathologia       Date:  2015-09-09       Impact factor: 2.574

8.  Invasive fatal rhino-orbito-cerebral mucormycosis in diabetic ketoacidosis.

Authors:  George Garas; Natasha Choudhury; Roy Farrell
Journal:  JRSM Short Rep       Date:  2010-12-01

9.  Epidemiological aspects and clinical outcome of patients with Rhinocerebral zygomycosis: a survey in a referral hospital in Iran.

Authors:  Vida Bozorgi; Mahshid Talebitaher; Neda Shalbaf; Nima Radmanesh; Fatemeh Nasri; Mohammad Mostafa Ansari-Ramandi
Journal:  Pan Afr Med J       Date:  2016-07-13

Review 10.  Mucormycosis: A deadly black fungus infection among COVID-19 patients in India.

Authors:  Naveen Kumar Choudhary; Amit K Jain; Rupesh Soni; Neha Gahlot
Journal:  Clin Epidemiol Glob Health       Date:  2021-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.